[Post-marketing surveillance].
作者信息
Leufkens H G, Heerdink E R
出版信息
Ned Tijdschr Geneeskd. 1996 Jun 1;140(22):1201-2; author reply 1202.
PMID:8692359
Abstract
摘要
相似文献
1
[Post-marketing surveillance].
Ned Tijdschr Geneeskd. 1996 Jun 1;140(22):1201-2; author reply 1202.
2
Blood dyscrasias and the pharmaceutical industry: screening surveillance and monitoring, and future drug development.血液系统疾病与制药行业：筛查、监测及未来药物研发
Eur J Haematol Suppl. 1996;60:128-9.
3
[Post-marketing surveillance].
Ned Tijdschr Geneeskd. 1996 Mar 16;140(11):620-1.
4
[Post-marketing surveillance].
Ned Tijdschr Geneeskd. 1996 Jun 1;140(22):1202.
5
Post-marketing surveillance of drugs.
Med J Aust. 1991 Apr 15;154(8):567.
6
Strategy for surveillance of adverse drug events.药品不良事件监测策略。
Food Drug Law J. 2007;62(3):605-16.
7
Post-marketing observational studies: my experience in the drug industry.上市后观察性研究：我在制药行业的经历。
BMJ. 2012 Jun 12;344:e3990. doi: 10.1136/bmj.e3990.
8
Mandatory post marketing studies.上市后强制研究。
Am J Ther. 2007 Jul-Aug;14(4):321. doi: 10.1097/MJT.0b013e3181468e21.
9
Post-marketing strategies for medicines.药品上市后策略
Clin Pharmacol Ther. 2008 Jan;83(1):24-5; discussion 25. doi: 10.1038/sj.clpt.6100427. Epub 2007 Nov 28.
10
[The need for 'postmarketing surveillance'].[上市后监测的必要性]
Ned Tijdschr Geneeskd. 1999 Apr 3;143(14):711-3.
Zotero 插件